Nervenarzt最新文献

Electroconvulsive therapy (ECT) is a clinically well-established, evidence-based procedure for the treatment of particularly severe or treatment-resistant psychiatric and neuropsychiatric disorders. A considerable number of patients who require ECT are unable to provide informed consent due to their medical condition. Both international and national studies show that restrictive laws and legal rulings can hinder or even prevent the use of ECT in patients lacking the capacity to provide informed consent or in cases of nonvoluntary treatment (coercive treatment). Patients with indications for ECT who lack the capacity to consent constitute a vulnerable group, often with no viable alternative therapy available. The decision to administer ECT to individuals lacking the capacity to consent, particularly as a nonvoluntary treatment, is highly complex in terms of legal and medical ethics aspects because depending on the circumstances, both administering and withholding ECT can profoundly impact the patient's fundamental rights. The available evidence shows that patients initially treated against their will exhibit good overall response rates, with equally high retrospective and prospective approval for therapy compared to patients who initially consented to treatment.Together with the medical ethics considerations the authors conclude that the use of ECT should adhere to the same ethical and normative standards as all other medical interventions. This also applies to cases involving involuntary treatment. Adopting a more restrictive approach to ECT compared to other medical measures is neither medically nor ethically justified. Structural and legal barriers restricting access to necessary treatment for patients with severe and potentially life-threatening conditions should be critically reviewed and, when possible and necessary, removed.

The International Statistical Classification of Diseases and Related Health Problems version 11 (ICD-11) represents a conceptual advance over ICD-10 in the classification of dementias. Although the syndromic classification in the chapter "Neurocognitive disorders" remains in principle unchanged, the introduction of severity levels and the central positioning of mental and behavioral symptoms enables a more precise coding of the clinical diagnoses. Furthermore, the introduction of mild neurocognitive disorder as a prodromal state of dementia is new. The clinical criteria developed by international experts, e.g., for frontotemporal dementia or Lewy body disease, are not yet sufficiently included in ICD-11. Biomarkers for the etiological diagnostics of dementia are also not mentioned, so that it is unclear which role they play in the disease classification in ICD-11. Due to the rapid development in the field of neurodegenerative diseases, regular updates would be desirable.

The classification of psychotic disorders has undergone a variety of changes. Since Karl Ludwig Kahlbaum's (Kahlbaum 1874) first descriptions of catatonic states and Emil Kraepelin's (Kraepelin 1883) nosological classification of psychotic syndromes in the second half of the nineteenth century, the diagnostic criteria for these disorders have been repeatedly modified, significantly impacting clinical practice. Eugen Bleuler (Bleuler 1911) coined the term "schizophrenia", emphasizing the disturbances in thinking, feeling and acting that he had observed. With the introduction of the 11th version of the International Classification of Diseases (ICD-11), several significant changes to the diagnostic criteria were introduced. First-line symptoms according to Schneider lost importance. The subtypes (e.g., paranoid, hebephrenic and catatonic schizophrenia) were also omitted and symptom and progression classifiers have been introduced instead. Finally, catatonia is now defined as an independent diagnostic entity, while in ICD-10 it was still assigned to schizophrenia under the code F20.2. This recognizes catatonia's independent, cross-diagnostic nature. Due to these symptom and progression classifiers, the ICD-11 now takes a more a hybrid categorical and dimensional approach to the diagnosis than the previous version.

Objective: Analysis of the frequency of comorbid Alzheimer's disease in patients with suspected idiopathic normal pressure hydrocephalus (iNPH) and its effects on the response to cerebrospinal fluid (CSF) drainage as well as analysis of the frequency of a vascular copathology in patients with suspected iNPH.

Material and methods: This was a prospective observational analysis of patients with suspected iNPH who underwent guideline-conform NPH routine diagnostics including CSF drainage during clinical routine diagnostics between 1 July 2022 and 30 June 2023. Patients were recruited via the departments of neurology, neurosurgery and psychiatry of the University Hospital Carl Gustav Carus in Dresden. Typical NPH imaging results were acquired from available magnetic resonance imaging (MRI) and computed tomography (CT) sectional images. Relevant sociodemographic, clinical, cognitive and CSF diagnostic parameters were acquired via patient chart review. The patients were categorized with respect to the CSF results according to the amyloid-tau-neurodegeneration (ATN) classification.

Results: During the observational period 33 patients (14 female, 19 male, mean age 74.6 ± 8.1 years) with suspected iNPH were analyzed. Of the patients 19 (57.6%) had a complete and 14 (42.4%) an incomplete Hakim's triad. The difference between the MoCA scores before and after CSF drainage varied between patients with and without a response to CSF drainage (F(1;22) = 5.725; p = 0.026). There was a trend that patients with a pathological corpus callosum angle and conspicuous Evans index (p = 0.052) as well as patients with a pathological corpus callosum angle, Evans index and complete clinical Hakim's triad (p = 0.055) more frequently show a response. The mean Fazekas score was 1.7. There was no correlation between the Fazekas score and response to CSF drainage. In 25 patients (75.8%) biomarkers for dementia and neurodegeneration were detected. According to the ATN classification 20 patients (80%) were categorized as A⁺T^-, 3 (12.0%) as A⁺T⁺ and 2 (8.0%) as A^-T^-. Patients classified as A⁺T⁺ and A⁺T^- did not respond more often to CSF drainage (p = 0.600).

Conclusion: The combined determination of the corpus callosum angle and the Evans index as well es their contextualization with clinical characteristics can possibly improve the prognostic evaluation regarding response to CSF draínage. Especially a comorbid amyloid pathology and a cerebral microangiopathy represent frequent copathologies of iNPH but the influence on the response to CSF drainage remains to be elucidated.

With the introduction of the 11th revision of the World Health Organization International Statistical Classification of Diseases and Related Health Problems (ICD-11), structural and content-related adjustments to the diagnostic guidelines for anxiety disorders were made, which are presented in this review article. Previously classified as "phobic disorders" and "other anxiety disorders" within the group "neurotic, stress-related, and somatoform disorders", in ICD-11 "anxiety- or fear-related disorders" now constitute a separate group. The core diagnoses of agoraphobia, social anxiety disorder, specific phobia, panic disorder and generalized anxiety disorder are retained, with the modification that agoraphobia and panic disorder can now be diagnosed separately and comorbidly. Within the framework of the lifespan perspective, separation anxiety disorder and selective mutism have been moved to the group "anxiety- or fear-related disorders". The diagnosis "mixed anxiety and depressive disorder" is now classified as "mixed depressive and anxiety disorder" in the group "affective disorders". In accordance with the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‑5), it is possible to code isolated panic attacks in addition to other mental or somatic disorders. Overall, ICD-11 follows the DSM‑5 classification of anxiety- and fear-related disorders in many respects. Furthermore, the omission of subcategorizations and a precise minimum number of required symptoms simplify the diagnostic criteria. Future studies will need to address questions regarding the diagnostic accuracy, clinical practicability and further operationalization of the ICD-11 diagnostic criteria for anxiety- or fear-related disorders.

The International Statistical Classification of Diseases and Related Health Problems version 11 (ICD-11) represents a conceptual advance over ICD-10 in the classification of dementias. Although the syndromic classification in the chapter "Neurocognitive disorders" remains in principle unchanged, the introduction of severity levels and the central positioning of mental and behavioral symptoms enables a more precise coding of the clinical diagnoses. Furthermore, the introduction of mild neurocognitive disorder as a prodromal state of dementia is new. The clinical criteria developed by international experts, e.g., for frontotemporal dementia or Lewy body disease, are not yet sufficiently included in ICD-11. Biomarkers for the etiological diagnostics of dementia are also not mentioned, so that it is unclear which role they play in the disease classification in ICD-11. Due to the rapid development in the field of neurodegenerative diseases, regular updates would be desirable.

The classification of psychotic disorders has undergone a variety of changes. Since Karl Ludwig Kahlbaum's (Kahlbaum 1874) first descriptions of catatonic states and Emil Kraepelin's (Kraepelin 1883) nosological classification of psychotic syndromes in the second half of the nineteenth century, the diagnostic criteria for these disorders have been repeatedly modified, significantly impacting clinical practice. Eugen Bleuler (Bleuler 1911) coined the term "schizophrenia", emphasizing the disturbances in thinking, feeling and acting that he had observed. With the introduction of the 11th version of the International Classification of Diseases (ICD-11), several significant changes to the diagnostic criteria were introduced. First-line symptoms according to Schneider lost importance. The subtypes (e.g., paranoid, hebephrenic and catatonic schizophrenia) were also omitted and symptom and progression classifiers have been introduced instead. Finally, catatonia is now defined as an independent diagnostic entity, while in ICD-10 it was still assigned to schizophrenia under the code F20.2. This recognizes catatonia's independent, cross-diagnostic nature. Due to these symptom and progression classifiers, the ICD-11 now takes a more a hybrid categorical and dimensional approach to the diagnosis than the previous version.

With the introduction of the 11th revision of the World Health Organization (WHO) "International Statistical Classification of Diseases and Related Health Problems" (ICD-11), structural and content-related adjustments were made to the diagnostic guidelines for affective disorders, which are presented in this review article. The update has resulted in some changes to the diagnostic classification of affective disorders, based on the American Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5). The ICD-11 assigns depressive symptoms to so-called clusters, the main symptoms of depressed mood and joylessness can be accompanied by cognitive, behavioral or neurovegetative symptoms. In the case of remission of depressive episodes, the ICD-11 distinguishes between partial and complete remission. A persistent depressive disorder is present if the depressive episode lasts continuously for more than 2 years. In future, bipolar disorder will be divided into type I and type II. Manic episodes can still only be coded in the context of bipolar disorders and cannot be diagnosed as an independent, separate disorder. The concept of persistent affective disorders in the ICD-10 is abandoned, dysthymia is categorized as a depressive disorder and cyclothymia as a bipolar disorder.